Macrolide Antibiotics

Correct Answer

B — Azithromycin

Rationale

Azithromycin is a macrolide antibiotic. Doxycycline is a tetracycline. Ciprofloxacin is a fluoroquinolone. Vancomycin is a glycopeptide. Recognizing azithromycin as the macrolide among agents from other antibiotic classes is the entire task here.

Correct Answer

D — The prototype macrolide and the original agent from which the class was developed

Rationale

Erythromycin is the prototype macrolide — the first agent of the class, discovered in the early 1950s, from which all subsequent macrolides were developed. Clarithromycin and azithromycin are semisynthetic derivatives developed to improve on erythromycin's pharmacokinetic and tolerability limitations. Knowing erythromycin's classification as the prototype macrolide is the task here.

Correct Answer

A — A semisynthetic macrolide derived from erythromycin

Rationale

Clarithromycin is a semisynthetic macrolide — it was derived from erythromycin by chemical modification of the erythromycin A molecule. Azithromycin is also a semisynthetic macrolide derived from erythromycin. Erythromycin itself is a naturally occurring macrolide produced by Streptomyces erythraeus. Knowing clarithromycin's classification as a semisynthetic erythromycin derivative is the task here.

Correct Answer

C — A 15-membered ring macrolide — the only azalide — derived from erythromycin

Rationale

Azithromycin is classified as an azalide — a subclass of macrolides defined by insertion of a nitrogen atom into the lactone ring, expanding it from 14 to 15 members. This structural distinction places azithromycin in the azalide subclass, making it the only clinically used azalide. Erythromycin and clarithromycin are 14-membered ring macrolides. Azithromycin is semisynthetic, derived from erythromycin. Knowing azithromycin's classification as an azalide is the task here.

Correct Answer

B — Bacteriostatic agents

Rationale

Macrolides are classified as bacteriostatic agents. Their binding to the 50S ribosomal subunit is reversible, so bacterial protein synthesis and growth can resume when drug concentrations fall — the defining feature of bacteriostatic activity. This distinguishes macrolides from bactericidal agents such as aminoglycosides and beta-lactams. Knowing the bacteriostatic classification of macrolides is the task here.

Correct Answer

A — Motilin receptor agonist

Rationale

Erythromycin is classified as a motilin receptor agonist — a pharmacological property entirely separate from its antibacterial mechanism. Motilin is an enteric hormone that stimulates gastric and small bowel smooth muscle contraction. Erythromycin's structural similarity to motilin allows it to bind and activate motilin receptors in the gastrointestinal tract, accelerating gastric emptying and increasing intestinal peristalsis. This prokinetic effect is responsible for the nausea, vomiting, abdominal cramping, and diarrhea that are the most common reasons for erythromycin discontinuation. At sub-antimicrobial doses, this same effect is deliberately exploited for the treatment of gastroparesis. This dual classification — macrolide antibiotic and motilin receptor agonist — is the defining pharmacological feature distinguishing erythromycin from the other macrolides.

Correct Answer

C — Macrolides reversibly bind the 50S subunit and block peptide chain elongation; tetracyclines reversibly bind the 30S subunit and block aminoacyl-transfer ribonucleic acid entry at the acceptor site

Rationale

Macrolides bind the 50S ribosomal subunit and block the exit tunnel through which the growing polypeptide chain passes, halting elongation. Tetracyclines bind the 30S ribosomal subunit and block the aminoacyl-transfer ribonucleic acid acceptor site, preventing delivery of the next amino acid. Both mechanisms are reversible — the drug dissociates when concentrations fall, and protein synthesis resumes, making both classes bacteriostatic in most contexts. Because the two classes target different subunits through different mechanisms, cross-resistance between them does not occur by default, and there is no additive effect from combining them at the same ribosomal site. Aminoglycosides (not macrolides) cause messenger ribonucleic acid misreading at the 30S subunit and are bactericidal through an irreversible mechanism.

Correct Answer

A — Azithromycin accumulates in tissue at concentrations 10 to 100 times higher than serum and has a tissue half-life of approximately 68 hours, maintaining intracellular drug concentrations long after dosing ends

Rationale

Azithromycin's extraordinary tissue penetration is the pharmacokinetic basis for its short and single-dose regimens. The drug is avidly concentrated in tissues — especially alveolar macrophages, neutrophils, and monocytes — reaching concentrations 10 to 100 times higher than concurrent serum levels. The tissue half-life of approximately 68 hours means that cells carrying high drug concentrations continue releasing azithromycin at infection sites for days after the last dose, maintaining antibacterial activity throughout the treatment course. The serum half-life, by contrast, is much shorter, and serum concentrations are relatively low — which explains why azithromycin is unreliable for bacteremia despite its tissue efficacy. Azithromycin does not have a prolonged active metabolite, and the 68-hour value refers to tissue half-life, not plasma half-life.

Correct Answer

D — Clarithromycin inhibits cytochrome P450 3A4, the primary enzyme metabolizing simvastatin, raising simvastatin plasma concentrations to myotoxic levels and risking myopathy or rhabdomyolysis

Rationale

Simvastatin is a cytochrome P450 3A4 substrate — its hepatic first-pass and systemic metabolism depend on this enzyme. Clarithromycin is a significant cytochrome P450 3A4 inhibitor, and when the two drugs are co-administered, simvastatin clearance is substantially reduced. Plasma simvastatin concentrations rise to levels associated with skeletal muscle toxicity, manifesting as myopathy (muscle pain and weakness with elevated creatine kinase) or the more severe rhabdomyolysis (massive muscle breakdown, myoglobinuria, and risk of acute kidney injury). The appropriate response is to hold simvastatin during the clarithromycin course or switch to a statin not metabolized by cytochrome P450 3A4, such as rosuvastatin or pravastatin. Erythromycin carries the same interaction with even higher potency; azithromycin does not because of its negligible cytochrome P450 3A4 inhibitory activity. The mechanism is hepatic enzyme inhibition, not renal competition or protein displacement.

Correct Answer

B — Macrolides directly block cardiac ion channels, delaying ventricular repolarization; risk of torsades de pointes is highest in patients with pre-existing QT prolongation, hypokalemia, hypomagnesemia, or concurrent QT-prolonging medications

Rationale

Macrolides prolong the corrected QT interval by blocking cardiac potassium channels responsible for ventricular repolarization, specifically the rapid delayed rectifier channel. Delayed repolarization prolongs the action potential and creates conditions for early afterdepolarizations that can trigger torsades de pointes — a potentially fatal polymorphic ventricular tachycardia. All three major macrolides carry this risk; azithromycin and erythromycin carry the greatest corrected QT prolongation potential in the class. Risk is amplified by factors that independently prolong the QT interval or reduce repolarization reserve: baseline corrected QT prolongation, hypokalemia, hypomagnesemia, bradycardia, advanced age, female sex, and concurrent use of other QT-prolonging agents such as antipsychotics, antiarrhythmics, and certain antiemetics. The mechanism is direct ion channel blockade, not cytochrome P450 inhibition in cardiac tissue or motilin receptor stimulation.

Correct Answer

A — Azithromycin's extensive tissue distribution results in relatively low serum concentrations that are often insufficient to maintain drug levels above the minimum inhibitory concentration in the bloodstream

Rationale

Azithromycin distributes so avidly into tissues that serum drug concentrations are substantially lower than concurrent tissue levels — the opposite of what most antibiotics demonstrate. For infections localized in tissues such as the lung, genital tract, or skin, this tissue accumulation is therapeutically advantageous because drug concentrations at the site of infection are high. For bacteremia, however, the infecting organisms are present in the bloodstream where drug concentrations are relatively low. Achieving sustained concentrations above the minimum inhibitory concentration for gram-negative bacteremia or even for more susceptible organisms is unreliable at standard azithromycin doses. This limitation is pharmacokinetic, specific to the tissue distribution pattern, and is not a universal rule about bacteriostatic agents. Azithromycin is not inactivated by serum proteins, and its hepatic metabolism does not accelerate in bacteremic patients.

Correct Answer

C — Cholestatic hepatitis mediated by hypersensitivity to the estolate ester; presenting with fever, right upper quadrant pain, elevated alkaline phosphatase and bilirubin, and eosinophilia typically 10 to 20 days after starting therapy

Rationale

Erythromycin estolate — the lauryl sulfate ester salt formulation of erythromycin — is associated with cholestatic hepatitis through a hypersensitivity mechanism directed at the estolate ester component. The reaction is characterized by fever, right upper quadrant pain, nausea, and jaundice with a cholestatic pattern of liver enzyme elevation (elevated alkaline phosphatase and bilirubin out of proportion to transaminases) and peripheral eosinophilia. The syndrome typically appears 10 to 20 days after starting therapy and resolves when the drug is stopped. Because the injury is mediated by the ester component specifically, other erythromycin formulations (stearate, ethylsuccinate) carry lower but not absent hepatotoxicity risk. The widespread use of clarithromycin and azithromycin has largely made this formulation obsolete. Macrolide ototoxicity exists but is reversible and dose-dependent, not from the estolate ester specifically; nephrotoxicity and bone marrow suppression are not macrolide adverse effects.

Correct Answer

D — Ribosomal methylation encoded by erm genes modifies the 23S ribosomal ribonucleic acid binding site so macrolides cannot bind; efflux pump upregulation actively expels macrolides from the bacterial cell before they reach the ribosome

Rationale

The two principal macrolide resistance mechanisms operate at different steps and through different molecular targets. Erm (erythromycin ribosome methylation) genes encode methyltransferase enzymes that methylate the adenine residue at position 2058 of 23S ribosomal ribonucleic acid within the 50S subunit. This modification prevents macrolides from binding their ribosomal target and confers cross-resistance to macrolides, lincosamides, and streptogramin B antibiotics — the MLSB resistance phenotype. Efflux pumps, encoded by mef genes in Streptococcus pneumoniae and other organisms, are membrane proteins that actively pump macrolides out of the bacterial cytoplasm before they accumulate to concentrations sufficient for ribosomal binding. Efflux pump resistance typically produces lower-level resistance compared to erm-mediated methylation. Neither mechanism involves drug hydrolysis. Both mechanisms can be encoded on plasmids or chromosomal elements.

Correct Answer

B — Clarithromycin and erythromycin inhibit cytochrome P450 3A4, the primary enzyme metabolizing colchicine, substantially raising colchicine plasma concentrations to potentially lethal levels

Rationale

Colchicine is primarily metabolized by cytochrome P450 3A4. When clarithromycin or erythromycin — both potent cytochrome P450 3A4 inhibitors — are co-administered, colchicine metabolism is markedly reduced and plasma concentrations rise substantially above the therapeutic range. Colchicine has a narrow therapeutic index and is severely toxic at elevated concentrations, causing gastrointestinal injury, bone marrow suppression, myopathy, and potentially multi-organ failure. The risk is highest in patients with renal impairment because colchicine is also partially renally cleared, but the primary mechanism of the interaction is the cytochrome P450 3A4 inhibition. When a macrolide is needed in a patient taking colchicine, azithromycin is the agent of choice because of its negligible cytochrome P450 3A4 inhibitory activity.

Correct Answer

D — Azithromycin produces negligible cytochrome P450 3A4 inhibition, avoiding the drug interaction that would raise simvastatin concentrations to myotoxic levels with clarithromycin or erythromycin

Rationale

The selection of azithromycin over clarithromycin in this patient is driven by the drug interaction risk, not by spectrum differences. Both agents cover the pathogens of community-acquired pneumonia including atypical organisms. Clarithromycin is a significant cytochrome P450 3A4 inhibitor; co-administration with simvastatin would substantially reduce simvastatin metabolism, raising plasma statin concentrations to levels associated with myopathy and rhabdomyolysis. Azithromycin's negligible cytochrome P450 3A4 inhibitory activity means it can be used safely alongside simvastatin without causing statin accumulation. The principle generalizes: when a macrolide is clinically indicated and the patient is taking any cytochrome P450 3A4-sensitive medication — simvastatin, lovastatin, colchicine, warfarin, cyclosporine, tacrolimus — azithromycin is the macrolide of choice. The selection here is a mechanism-based pharmacological decision, not a spectrum or tolerability decision.

Correct Answer

B — Azithromycin directly blocked cardiac potassium channels responsible for ventricular repolarization, delaying the corrected QT interval; this patient's pre-existing cardiovascular disease places him at elevated risk for torsades de pointes

Rationale

Azithromycin, along with erythromycin, carries the greatest corrected QT prolongation potential among the macrolides through direct blockade of cardiac potassium channels — specifically the rapid delayed rectifier channel — responsible for ventricular repolarization. Delayed repolarization prolongs the action potential duration and the corrected QT interval. In this patient, the corrected QT has extended from 440 to 520 milliseconds on azithromycin, a clinically significant increase. Pre-existing cardiovascular disease is an established independent risk factor for macrolide-associated corrected QT prolongation and subsequent torsades de pointes. A corrected QT interval above 500 milliseconds is generally considered a threshold warranting strong consideration of drug discontinuation. Azithromycin does not prolong the QT through cytochrome P450 mechanisms in cardiac tissue, and motilin receptors are gastrointestinal, not cardiac. Azithromycin does prolong the QT interval — this is well-documented.

Correct Answer

A — Azithromycin is avidly concentrated in cells and tissues to levels 10 to 100 times higher than serum and has a tissue half-life of approximately 68 hours; infected cells release drug at the infection site for days after the single dose, maintaining intracellular concentrations that inhibit Chlamydia trachomatis

Rationale

Single-dose azithromycin therapy for Chlamydia trachomatis exploits two complementary pharmacokinetic properties. First, azithromycin concentrates in cells and tissues — particularly the phagocytic cells and epithelial cells where Chlamydia trachomatis resides as an obligate intracellular pathogen — reaching concentrations 10 to 100 times higher than concurrent serum levels. Second, the tissue half-life of approximately 68 hours means that cells loaded with azithromycin continue releasing drug slowly at the site of infection for several days after the single dose is taken. This sustained intracellular drug delivery maintains concentrations above the minimum inhibitory concentration for Chlamydia trachomatis throughout the necessary treatment period, enabling effective single-dose therapy. Serum drug concentrations, by contrast, are relatively low and fall quickly. There is no long-acting active metabolite, and azithromycin's 50S ribosomal binding is reversible, not irreversible.

Correct Answer

C — Clarithromycin inhibited cytochrome P450 3A4, reducing colchicine metabolism and raising colchicine to toxic concentrations; the patient's renal impairment further impaired colchicine clearance

Rationale

This presentation is classic colchicine toxicity from a drug interaction. Clarithromycin is a potent cytochrome P450 3A4 inhibitor. Colchicine is primarily metabolized by cytochrome P450 3A4 and has a narrow therapeutic index. Inhibition of this enzyme substantially reduces colchicine clearance, raising plasma concentrations to toxic levels. The patient's stage 3 chronic kidney disease adds a second clearance impairment — colchicine is partially renally eliminated — amplifying the toxicity risk. Colchicine toxicity is multisystemic: gastrointestinal mucosal injury, bone marrow suppression causing leukopenia, and myopathy. This combination is contraindicated in patients with renal or hepatic impairment. Azithromycin, with negligible cytochrome P450 3A4 inhibitory activity, should have been selected instead.